NCT05821933View on ClinicalTrials.gov

RC108 Combine With Furmonertinib With/Without Toripalimab in Patients With EGFR-mutated NSCLC

PHASE1/PHASE2RecruitingINTERVENTIONAL

Enrollment

106

Participants

Timeline

Start Date

September 7, 2023

Primary Completion Date

September 1, 2025

Study Completion Date

September 1, 2026

Conditions

NSCLC

Interventions

DRUG

RC108

RC108 plus Furmonertinib and/or Toripalimab

Trial Locations (1)

100021

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

All Listed Sponsors

lead

RemeGen Co., Ltd.

INDUSTRY